Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 2,689 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Normal saline solution Clear all
Recruiting Phase 4 Interventional

Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

NCT07133880
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

Oxidative Stress and Surgical Recovery

NCT04732000
View directory record Official record
Conditions
Surgical Recovery, Pain, Postoperative
Interventions
N-acetyl cysteine, Normal Saline
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 23, 2026, 3:32 PM EDT
Withdrawn Phase 4 Interventional

Botulinum Toxin-A for Hidradenitis Suppurativa

NCT06237465
View directory record Official record
Conditions
Hidradenitis Suppurativa, Hidradenitis Suppurativa \(HS\), Hidradenitis Suppurativa, Acne Inversa
Interventions
Normal saline, Botulinum toxin type A
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Guilford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 1 Interventional

GIP: Glucose-dependent Insulinotropic Peptide

NCT00239707
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
GIP, Modified GIP, Normal Saline
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2013 · Synced Oct 23, 2026, 3:32 PM EDT
Terminated Not applicable Interventional

Chronic Post Breast Surgery Pain

NCT00847067
View directory record Official record
Conditions
Breast Cancer
Interventions
Paravertebral block, Sham injections
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Not applicable Interventional

A Study of Immediate and Delayed Closure of Type II and IIIa Open Tibia Fractures

NCT01315392
View directory record Official record
Conditions
Type II and IIa Open Tibia Fractures
Interventions
delayed closure, immediate wound closure
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
15 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 1Phase 2 Interventional

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

NCT05683834
View directory record Official record
Conditions
Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
Interventions
Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 25 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Not applicable Interventional

Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients

NCT02470299
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Ketorolac, Placebo
Drug · Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

NCT02592798
View directory record Official record
Conditions
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
Abatacept, Normal Saline, D5W
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 23, 2026, 3:32 PM EDT
Recruiting Phase 2 Interventional

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

NCT05947955
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Infections
Interventions
Rhu-pGSN, normal saline
Drug
Lead sponsor
BioAegis Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 3:32 PM EDT
Active, not recruiting Phase 2 Interventional

Peripheral Modulation of Muscle Stiffness and Spasticity

NCT03306615
View directory record Official record
Conditions
Muscle Spasticity
Interventions
Hyaluronidase, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 3:32 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

NCT04504825
View directory record Official record
Conditions
AL Amyloidosis
Interventions
CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
26
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 3:32 PM EDT
Not yet recruiting Phase 2 Interventional

Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

NCT07683026
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Golimumab, Placebo (matching golimumab)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years to 44 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Not applicable Interventional Results available

A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy

NCT00294684
View directory record Official record
Conditions
Biliary Atresia
Interventions
Corticosteroids, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Up to 6 Months
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 23, 2026, 3:32 PM EDT
Terminated Phase 4 Interventional Results available

Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.

NCT03756454
View directory record Official record
Conditions
Clostridia Difficile Colitis, Clostridium; Sepsis
Interventions
Bezlotoxumab, Normal Saline
Biological · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 23, 2026, 3:32 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis

NCT04548583
View directory record Official record
Conditions
Crohn Colitis
Interventions
Remestemcel-L, Placebo
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

Reducing INfection at the Surgical SitE With Antibiotic Irrigation During Ventral Hernia Repair (RINSE Trial)

NCT03945357
View directory record Official record
Conditions
Ventral Hernia Repair
Interventions
Gemcitabine/ clindamycin, Normal saline
Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 4 Interventional Results available

IV Acetaminophen as an Analgesic Adjunct

NCT02621619
View directory record Official record
Conditions
Acute Pain
Interventions
IV acetaminophen + 0.5 mg IV hydromorphone, Normal saline + 0.5 mg IV hydromorphone
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
65 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 23, 2026, 3:32 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Intravenous Neridronic Acid in CRPS

NCT03530345
View directory record Official record
Conditions
Complex Regional Pain Syndrome (CRPS)
Interventions
Neridronic acid 100 mg, Placebo
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

ivWatch Model 400: Device Validation for Infiltrated Tissues

NCT02123745
View directory record Official record
Conditions
Infiltration of Peripheral IV Therapy
Interventions
The ivWatch Model 400
Device
Lead sponsor
ivWatch, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Williamsburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF

NCT00661622
View directory record Official record
Conditions
Uveal Melanoma, Liver Metastases
Interventions
GM-CSF, Embolization
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 23, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Recombinant CMV gB Vaccine in Postpartum Women

NCT00125502
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
CMV gB vaccine, MF59 adjuvant, Placebo
Biological · Drug
Lead sponsor
Robert Pass, MD
Other
Eligibility
14 Years to 40 Years · Female only
Enrollment
464 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2010
U.S. locations
2
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 23, 2026, 3:32 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris

NCT01920477
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
Ofatumumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Atlanta, Georgia • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 23, 2026, 3:32 PM EDT
Terminated Phase 2 Interventional Results available

High-Dose Deferoxamine in Intracerebral Hemorrhage

NCT01662895
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Deferoxamine, Normal saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 23, 2026, 3:32 PM EDT